Futurity reported on research led by biomedical engineering Jonathan Lovell that found an experimental nanoparticle-based flu vaccine consisting of disease-fighting proteins was proven effective in preclinical studies. The technology could boost the effectiveness and accelerate the production of seasonal flu vaccines.